Original paper
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
Volume: 36, Issue: 15_suppl, Pages: 5506 - 5506
Published: May 20, 2018
Abstract
5506 Background: Bevacizumab (BEV) is approved in recurrent ovarian cancer (rOC) for patients not previously treated with the drug. Our study aimed at evaluating whether the addition of BEV to a platinum-based chemotherapy prolongs progression-free survival (PFS) for rOC patients who had already received it during first line. Methods: FIGO stage IIIB-IV rOC patients relapsing at least 6 months after last dose of platinum, who had received BEV...
Paper Details
Title
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
Published Date
May 20, 2018
Journal
Volume
36
Issue
15_suppl
Pages
5506 - 5506